Earnings ·
Wave Life Sciences Ltd. reported financial results for the quarter ended June 30, 2026, recognizing $2.3 million in…
WVEWave Life Sciences, Inc.
Wave Life Sciences Ltd. reported financial results for the quarter ended June 30, 2026, recognizing $2.3 million in revenue compared to $8.7 million in the prior year period. The company incurred a net loss of $69.4 million against $50.5 million previously, driven by research and development expenses of $51.3 million and general and administrative costs of $24.8 million. Cash, cash equivalents, and marketable securities totaled $490.6 million as of June 30, 2026, providing an expected cash runway into the third quarter of 2028. Clinically, dosing has commenced in the Phase 2a multidose portion of the INLIGHT trial for WVE-007 in obesity, with combination and maintenance trials scheduled to initiate in the second half of 2026. Additionally, an FDA meeting regarding a potential accelerated approval pathway for WVE-006 in alpha-1 antitrypsin deficiency is set for late summer 2026, while a clinical trial application for WVE-008 remains on track for the second half of 2026. Wave Life Sciences Ltd. operates as a clinical-stage biotechnology company focused on developing RNA medicines to treat rare and common disorders.